Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -59.27% is 13% above its 5-year average of -68.15%, near the high end of its 5-year range (-270.72%–-21.73%).
As of the fiscal period ended Tuesday, June 30, 2026. 32.78% above its 12-month average of -88.18%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -59.27%.
RETURN ON EQUITY (ROE)
-59.27%
RETURN ON EQUITY (ROE) AVG TTM
-88.18%
RETURN ON EQUITY (ROE) AVG 3Y
-133.12%
RETURN ON EQUITY (ROE) AVG 5Y
-68.15%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+32.78%
CURRENT VS 3Y AVG
+55.47%
CURRENT VS 5Y AVG
+13.03%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-39.66%
median of 590 covered companies
CURRENT VS SECTOR MEDIAN
-49.47%
vs the sector median at left
Invivyd, Inc.
Market Cap
$248.06M
Return on Equity (ROE)
-59.27%
TTM Avg
-88.18%
3Y Avg
-133.12%
5Y Avg
-68.15%
Market Cap
$249.23M
Return on Equity (ROE)
-43.11%
TTM Avg
-35.75%
3Y Avg
-28.47%
5Y Avg
-12.53%
Market Cap
$246.67M
Return on Equity (ROE)
-695.56%
TTM Avg
-3698.55%
3Y Avg
-1897.26%
5Y Avg
-1268.80%
Market Cap
$242.35M
Return on Equity (ROE)
N/A
TTM Avg
35.05%
3Y Avg
64.68%
5Y Avg
-167.54%
Market Cap
$243.62M
Return on Equity (ROE)
N/A
TTM Avg
-1340.59%
3Y Avg
-55.32%
5Y Avg
-61.68%
Market Cap
$240.98M
Return on Equity (ROE)
-118.58%
TTM Avg
62.37%
3Y Avg
-376.78%
5Y Avg
-340.60%
Market Cap
$241.56M
Return on Equity (ROE)
-27.27%
TTM Avg
-92.43%
3Y Avg
-64.95%
5Y Avg
-57.80%
Market Cap
$256.22M
Return on Equity (ROE)
-47.25%
TTM Avg
-42.23%
3Y Avg
-50.43%
5Y Avg
-29.25%
Market Cap
$240.97M
Return on Equity (ROE)
N/A
TTM Avg
-125.28%
3Y Avg
-42.20%
5Y Avg
-43.41%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Invivyd, Inc. (IVVD) | $248.06M | -59.27% | -88.18% | -133.12% | -68.15% |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $249.23M | -43.11% | -35.75% | -28.47% | -12.53% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $246.67M | -695.56% | -3698.55% | -1897.26% | -1268.80% |
| Galectin Therapeutics Inc. (GALT)vs › | $242.35M | N/A | 35.05% | 64.68% | -167.54% |
| Lifecore Biomedical, Inc. (LFCR)vs › | $243.62M | N/A | -1340.59% | -55.32% | -61.68% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $240.98M | -118.58% | 62.37% | -376.78% | -340.60% |
| InflaRx N.V. (IFRX)vs › | $241.56M | -27.27% | -92.43% | -64.95% | -57.80% |
| Century Therapeutics, Inc. (IPSC)vs › | $256.22M | -47.25% | -42.23% | -50.43% | -29.25% |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $240.97M | N/A | -125.28% | -42.20% | -43.41% |
| Anika Therapeutics, Inc. (ANIK)vs › | $258.56M | -2.76% | -22.10% | -22.09% | -15.95% |
ROE
-59.3%
ROA
-49.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -59.27% |
| 2026-03-31 | -38.22% |
| 2025-12-31 | -21.73% |
| 2025-09-30 | -64.32% |
| 2025-06-30 | -257.38% |
| 2025-03-31 | -263.57% |
| 2024-12-31 | -251.60% |
| 2024-09-30 | -270.72% |
| 2024-06-30 | -144.93% |
| 2024-03-31 | -115.87% |
| 2023-12-31 | -111.93% |
| 2023-09-30 | -68.79% |
| 2023-06-30 | -62.23% |
| 2023-03-31 | -53.86% |
| 2022-12-31 | -67.79% |
| 2022-09-30 | -74.13% |
| 2022-06-30 | -71.13% |
| 2022-03-31 | -62.86% |
| 2021-12-31 | -40.64% |
| 2021-09-30 | -32.79% |
